Latest News
-
Tuesday - June 19, 2018
Bayer issues new bonds with a volume of 15 billion U.S. dollars
Successful international placement secures long-term financing of the Monsanto acquisition / Issue of eight tranches with maturities of three to 30 years was approximately three times oversubscribed » more
-
Monday - June 11, 2018
25th International Pig Veterinary Society Congress:
Bayer drives scientific exchange and digital tools to advance swine well-being and health
Global experts at 7th International Bayer Pig Symposium address topics key to swine production: piglet and sow management, biosecurity and responsible use of antibiotics / Bayer launches BCS SowDition and Power Pigs, smartphone apps. to help swine professionals analyse and track body condition scores of sows, as well as learn more about pig health and well-being solutions in an augmented reality-based game » more
-
Thursday - June 7, 2018
Bayer closes Monsanto acquisition » more
-
Monday - June 4, 2018
Bayer plans closing of Monsanto acquisition on June 7
Largest acquisition in company history to double size of agriculture business / Leading innovation engine in agriculture with pro forma R&D investment of 2.4 billion euros in 2017 / Transaction anticipated to generate significant value / Bayer strengthens commitment to sustainability and stakeholder engagement / Bayer to remain company name » more
-
Sunday - June 3, 2018
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer resolves capital increase with subscription rights to finance the acquisition of Monsanto
Final equity measure associated with the acquisition / Stockholders can acquire 2 new shares for every 23 shares they hold for 81.00 euros per new share » more
-
Friday - June 1, 2018
Bayer Science & Education Foundation launches new round of funding:
Bayer Foundation – EUR 350,000 for innovative project ideas
Support for study projects around the world in life sciences, agricultural science, chemistry and medicine / Special programs for teacher training in biology and chemistry as well as for health profession careers / EUR 50.000 extra budget for students from African countries in Germany / Applications now being accepted online through July 18, 2018 » more
-
Friday - June 1, 2018
Not intended for U.S. and UK Media - Translational research and clinical development collaboration:
Bayer and MD Anderson Cancer Center to collaborate on development of novel cancer treatments
5-year agreement to accelerate early clinical development of selected Bayer drug candidates / Collaboration part of Bayer’s focused segment leadership strategy in oncology » more
-
Tuesday - May 29, 2018
U. S. Department of Justice conditionally approves Bayer’s proposed acquisition of Monsanto
Operations of Bayer and Monsanto to be integrated as soon as divestments to BASF have been accomplished » more
-
Tuesday - May 29, 2018
Not intended for U.S. and UK Media
U.S. FDA accepts larotrectinib New Drug Application and grants priority review » more
-
Friday - May 25, 2018
Annual Stockholders’ Meeting 2018 » more
-
Friday - May 25, 2018
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:
Bayer is making good progress strategically
Acquisition of Monsanto expected to be closed in the near future / 2017 sales and earnings at the prior-year level / Dividend to be raised for the eighth time in succession – to 2.80 euros per share / Start to fiscal 2018 overshadowed by currency effects » more
-
Tuesday - May 22, 2018
BayG.A.P. online training:
Bayer launches online training in good agricultural practices
Free online course in English starts on May 28 2018. Registration open now / Portuguese and Spanish version planned for second half of 2018 / BayG.A.P. online training in Integrated Pest Management, residue management and pollinator health helps farmers comply with international standards on Good Agricultural Practices » more
-
Thursday - May 17, 2018
Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 54th Annual Meeting:
Bayer highlights latest oncology research at ASCO 2018
Clinical research to be presented from Bayer’s growing oncology portfolio, including radium-223 dichloride, sorafenib, regorafenib, copanlisib and other pipeline compounds » more
-
Thursday - May 17, 2018
Disappointing verdict requires in-depth analysis
General Court of the European Union decides that neonicotinoid restrictions imposed by European Commission in 2013 were lawful / Bayer will assess the verdict’s consequences and potential legal options » more
-
Friday - May 11, 2018
Not intended for U.S. and UK Media
Bayer receives approval for Eylea® in China
Eylea® gains approval in China for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration » more
-
Tuesday - May 8, 2018
CVBD® World Forum: Communication is key to managing vector-borne diesease threats in veterinary practice
Communications tools are needed to help achieve more meaningful outcomes in vector-borne disease prevention / The 13th CVBD® (Companion Vector-Borne Diseases) World Forum saw parasitologists, veterinary clinicians and epidemiology experts from around the world discuss vector-borne disease threats » more
-
Monday - May 7, 2018
Bayer announces Executive Leadership Team for new Crop Science division
Liam Condon to lead newly combined organization » more
-
Friday - May 4, 2018
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer concludes process to sell Covestro
14.2 percent interest sold for 2.2 billion euros / 6.8 percent of shares retained to repay exchangeable bond » more
-
Thursday - May 3, 2018
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer initiates full separation from Covestro
Accelerated bookbuilding process started for 14.2 percent » more
-
Thursday - May 3, 2018
First quarter of 2018
Bayer: Operational business held back by currency effects – Major progress with Monsanto acquisition
Group sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros / EBITDA before special items down year on year at 2.896 billion euros due to currency effects – level with prior-year quarter on a currency-adjusted basis / Sales increase at Pharmaceuticals (Fx & portfolio adj.) / Consumer Health down year on year, as expected / Sales of Crop Science match strong prior-year quarter (Fx & portfolio adj.) / Animal Health raises sales (Fx & portfolio adj.) and earnings / Net income declines by 6.2 percent to 1.954 billion euros / Core earnings per share down 1.3 percent at 2.28 euros / European Commission and additional regulators conditionally approve Monsanto acquisition / Currency adjusted Group outlook for 2018 confirmed » more
Copyright @ Bayer AG